CISCRP event to boost public awareness of clinical research The AWARE for All virtual event series aims to educate and engage the public as important partners in clinical trials and development of new treatments.
The Center for Information and Study on Clinical Research Participation (CISCRP) has announced its second annual AWARE for All series of virtual events. The series is intended to get members of the public more aware of the benefits of clinical research and trial participation.
The series of five individual events, each targeted at a different region, are scheduled from April through November 2021. The focus of the content is to engage a diverse range of community members, to help ensure inclusive and representative trial participant populations down the road.
Incorporating The Voices Of Parents And Children In Pediatric Clinical Trials
By Annick de Bruin and Shipra Patel, M.D.
A survey of families provides critical insights about their motivations and challenges.
Ensuring the health and well-being of children is essential in any setting, but pediatric clinical trials present an especially vulnerable environment in which children’s safety is paramount. Indeed, pediatric trials are far more complex and multifaceted than simply evaluating a therapy in the context of a child’s disease or illness. They are a family affair that must accommodate the diverse needs of parents, siblings, and often extended family members who care for children with chronic and acute illnesses.
Plain Language Summary Publication of Key Results from Bayer’s Phase 3 ARAMIS Trial Published in Future Oncology
Share Article
The Center for Information and Study on Clinical Research Participation (CISCRP) and Oxford PharmaGenesis worked together with Bayer, an ARAMIS trial investigator and oncologist, an ARAMIS trial participant, and a prostate cancer patient advocate Dr. Fizazi, Mr. Blue and Mr. Nowak, respectively to write a plain language summary publication (PLSP) of the 2020 New England Journal of Medicine article on the ARAMIS trial. Clinical trials are life. Very simply, for us patients, clinical trials are our life force,” wrote Mr. Nowak, a patient author. “Clinical trials have become so advanced.
Janssen s Best Practices For Patient Diversity Success
By Ed Miseta, Chief Editor, Clinical Leader
Follow Me On Twitter @EdClinical
As devastating as the COVID pandemic has been, one positive result is the increased attention it has shed on the pharmaceutical industry. Because of the quest to stop the spread of COVID and save lives, the public is now more aware of the difficulty of finding cures and vaccines, and the need for clinical trials. One report has even showed an improvement in the reputation of pharma.
“With COVID there s a greater understanding about clinical research,” said Cassandra Smith, director, diversity & inclusion in clinical trials at Janssen, speaking on a November 2020 Clinical Leader Live panel on patient diversity. “There s never been another time when people were discussing trials and clinical research at dinner tables and in social circles. People are now more aware of clinical research and have a better understanding of what it is. It s unfortuna
Clinical trials and the diversity principle
If they were ever really hidden, 2020 revealed the expensive-sounding problems limiting diversity in clinical trials. Solutions are overdue.
by Harry Yeates, Strategy Director, Langland
For years, maybe decades, a few minutes in PubMed or Google has provided all the evidence the interested observer needs to learn that there’s a problem with the equitable representation of diverse people in clinical trials. It reaches across various aspects of demography – including age, gender, sexual orientation, socioeconomic status and geography – and is particularly visible when it comes to minority populations. For those people, the lesson has been rather more tangible – in the absence both of clinical trials themselves as a care option, and medicines proven to be effective for them.